Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 166

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 166
---
 to the Company’s Report on Form 6-K, filed with the SEC on January 17, 2025).                              |
| 10.17  |     | Registration Rights Agreement, dated January 15, 2025, by and between C/M Capital Master Fund, LP, and Biodexa Pharmaceuticals PLC (incorporated by reference to Exhibit 10.2 to the Company’s Report on Form 6-K, filed with the SEC on January 17, 2025).                              |
| 19.1   |     | Insider Trading Policy (incorporated by reference to Exhibit 11.1 of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 11, 2025).                                                                                               |
| 21.1   |     | Subsidiaries of Biodexa Pharmaceuticals PLC (incorporated by reference to Exhibit 8.1 of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 11, 2025).                                                                           |
| 23.1*  |     | Consent of PKF Littlejohn LLP, independent registered public accounting firm.                                                                                                                                                                                                            |
| 23.2*  |     | Consent of Forvis Mazars LLP, independent registered public accounting firm.                                                                                                                                                                                                             |
| 23.3*  |     | Consent of Stephenson Harwood LLP (included in Exhibit 5.1).                                                                                                                                                                                                                             |
| 23.4*  |     | Consent of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. (included in Exhibit 5.2).                                                                                                                                                                                                  |
| 24.1*  |     | Powers of Attorney (included on signature page).                                                                                                                                                                                                                                         |
| 97.1   |     | Clawback Policy (incorporated by reference to Exhibit 97.1 to the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC on April 19, 2024).                                                                                                      |
| 107*   |     | Filing Fee Table.                                                                                                                                                                                                                                                                        |

__

* To be filed by amendment.

| 

# | Management contract or compensatory plan or arrangement. |
| † | Certain portions of this exhibit (indicated by asterisks) have been omitted because they